Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

#ESC26: Arrowhead claims safety edge over Ionis as triglyceride battle draws closer

MUNICH — Arrowhead is on course to crash Ionis Pharmaceuticals’ party. Arrowhead’s RNA interference drug Redemplo looked safer as well as effective in two late-stage trials in patients with high levels of dangerous fatty molecules called ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at endpoints.news →

More in Health & Medicine

More from Sunday 30 August →